Celularity (NASDAQ: CELU)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-09 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.480 | ||||||
REV | 5.935M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Celularity (NASDAQ: CELU) through any online brokerage.
Other companies in Celularity’s space includes: Immunovant (NASDAQ:IMVT), IDEAYA Biosciences (NASDAQ:IDYA), Centessa Pharmaceuticals (NASDAQ:CNTA), Eagle Pharmaceuticals (NASDAQ:EGRX) and Altimmune (NASDAQ:ALT).
The latest price target for Celularity (NASDAQ: CELU) was reported by HC Wainwright & Co. on Wednesday, June 22, 2022. The analyst firm set a price target for 15.00 expecting CELU to rise to within 12 months (a possible 307.61% upside). 5 analyst firms have reported ratings in the last year.
The stock price for Celularity (NASDAQ: CELU) is $3.68 last updated June 24, 2022, 8:00 PM UTC.
There are no upcoming dividends for Celularity.
Celularity’s Q2 earnings are confirmed for Tuesday, August 9, 2022.
There is no upcoming split for Celularity.
Celularity is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.